Dutch healthcare technology company Philips has unveiled its ECG AI Marketplace to enhance cardiac diagnostics by centralising access to AI-powered tools.
The platform, which integrates multiple vendor offerings, aims to streamline the implementation of AI diagnostics in cardiac care.
Anumana’s FDA-approved LEF algorithm is the first third-party solution available on the platform, marking a significant step in improving early cardiac diagnosis.
The ECG AI Marketplace allows US hospitals and health systems to incorporate validated algorithms into their existing Philips infrastructure.
The integration provides cardiac care teams with direct access to a wide range of AI tools, expediting ECG result reviews and patient diagnoses.
By managing vendor connections, the platform also reduces operational costs and improves efficiency by eliminating the need for hospital IT resources to manage multiple interfaces.
Philips ambulatory monitoring and diagnostics business leader Stefano Folli said: “Through the Philips ECG AI Marketplace, we’re building a more flexible and connected approach to innovation in cardiac care.
“The Philips ECG AI Marketplace meets a growing need for easier access and management of AI-enabled tools to improve the healthcare experience for clinicians and patients.
“Our collaboration with Anumana is a strong example of how these tools can support both earlier detection of heart diseases and accelerate patient care.”
Anumana’s LEF algorithm, now integrated across Philips’ ECG portfolio, analyses a standard 12-lead resting ECG to detect reduced ejection fraction, an early sign of heart failure.
With the inclusion in the Philips ECG AI Marketplace, healthcare providers can access AI-driven cardiac insights during routine ECG procedures, facilitating timely and informed care.
The collaboration with Anumana is part of Philips’ ongoing efforts to expand its ECG ecosystem to include third-party solutions.
By enhancing access to AI diagnostics, Philips aims to improve early detection and management of cardiovascular diseases.
Anumana president and COO Simos Kedikoglou said: “We’re proud to be the flagship offering on the Philips ECG AI Marketplace.
“Working with Philips expands access to our ECG-AI technology through a trusted platform, starting with our cleared LEF algorithm and extending to our full suite of point-of-care algorithms as they receive FDA regulatory clearance.
“Anumana’s AI algorithms, including for LEF detection, have been extensively evaluated in studies involving more than 150,000 patients and are supported by nearly 100 peer-reviewed publications.
“By making early detection tools available across multiple platforms, this collaboration helps clinicians intervene sooner, reflecting a shared commitment to improving outcomes for patients at risk of heart failure.”
